Maintenance therapy containing metformin and/or zyflamend for advanced prostate cancer: A case series

Mehmet Asim Bilen, Sue Hwa Lin, Dean G. Tang, Kinjal Parikh, Mong Hong Lee, Sai Ching J. Yeung, Shi Ming Tu

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality. Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap. We propose a maintenance regimen with metformin and/or Zyflamend that targets cancer stem cells and the tumor microenvironment to keep the cancer dormant and prevent it from activation from dormancy. Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.

Original languageEnglish (US)
Article number471861
JournalCase Reports in Oncological Medicine
Volume2015
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Maintenance therapy containing metformin and/or zyflamend for advanced prostate cancer: A case series'. Together they form a unique fingerprint.

Cite this